|
March 2008
Investigational GnRH blocker shows potential for advanced prostate cancer
March 27, 2008
MILAN (Reuters Health) - The investigational gonadotropin-releasing hormone (GnRH) antagonist degarelix is as effective as standard androgen deprivation therapy in men with prostate cancer, according to phase III results announced at the 23rd Annual Meeting of the European Association of Urology (EAU).
Enzastaurin shows promise as second- or third-line therapy in NSCLC
March 27, 2008
NEW YORK (Reuters Health) - Enzastaurin, an oral serine/threonine kinase inhibitor, halted disease progression in some patients with metastatic non-small-cell lung cancer (NSCLC) in a single-arm, phase II study published in the March 1 issue of the Journal of Clinical Oncology.
Nonclinical factors affect odds of breast cancer patients having sentinel node biopsy
March 27, 2008
NEW YORK (Reuters Health) - The likelihood that a woman with early breast cancer will undergo sentinel lymph node biopsy -- as opposed to the more invasive axillary lymph node dissection -- depends in part on sociodemographic characteristics and insurance status, as well as clinical factors, according to a new study.
Cancer survivors need organized preventive care
March 25, 2008
NEW YORK (Reuters Health) - As oncologists become less involved in the care of patients who have survived cancer, cancer-related screening decreases significantly, a study shows.
First-line EGFR inhibition may benefit selected lung cancer patients
March 21, 2008
NEW YORK (Reuters Health) - There is "strong evidence" that selected groups of patients with advanced non-small cell lung cancer (NSCLC) may benefit from first-line therapy with an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, according to the authors of a report in the March issue of the Journal of Thoracic Oncology.
Cephalon wins U.S. approval of Treanda for CLL
March 21, 2008
WASHINGTON (Reuters) - Cephalon Inc has won approval from the U.S. Food and Drug Administration to sell Treanda (bendamustine) to treat patients with chronic lymphocytic leukemia, or CLL, the company said on Thursday.
Ovarian cancer risk lower with longer time on Pill
March 20, 2008
NEW YORK (Reuters Health) - For each year that a woman takes an oral contraceptive, her risk of ovarian cancer is reduced by about 5 percent on average, report investigators from the University of Hawaii.
Locally advanced breast cancer more deadly in obese
March 14, 2008
WASHINGTON (Reuters) - Women with locally advanced breast cancer who are overweight have a worst prognosis than their slimmer counterparts, U.S. researchers reported on Friday.
Many lymphoma survivors have psychological scars
March 14, 2008
NEW YORK (Reuters Health) - Almost 40 percent of survivors of non-Hodgkin's lymphoma report some degree of emotional distress in the years after diagnosis, according to North Carolina-based researchers.
Advances in non-Hodgkin lymphoma survival are accelerating
March 14, 2008
NEW YORK (Reuters Health) - Long-term survival among patients with non-Hodgkin lymphoma (NHL) has improved substantially since the 1990s, epidemiologists in Germany report in the Archives of Internal Medicine for March 10.
Testing for colorectal cancer on the rise, but barriers to screening still exist
March 14, 2008
NEW YORK (Reuters Health) - The proportion of older adults undergoing screening for colorectal cancer increased overall from 2002 to 2006, according to data from the Centers for Disease Control and Prevention. However, disparities still exist, with low uptake particularly among racial minorities and individuals with no health insurance.
Combination therapy effective against multiple myeloma
March 13, 2008
NEW YORK (Reuters Health) - Treatment with a combination of clarithromycin, lenalidomide and dexamethasone is successful in most patients with newly diagnosed symptomatic multiple myeloma, according to New York-based researchers.
Presurgical test predicts breast cancer response to erlotinib
March 13, 2008
NEW YORK (Reuters Health) - A short-term presurgical trial of erlotinib (Tarceva) in patients with stage 1 to IIIA breast cancer may predict which patients will respond to erlotinib treatment after tumor resection.
Follicular NHL responds well to radioimmunotherapy after chemo
March 13, 2008
NEW YORK (Reuters Health) - In patients with advanced follicular non-Hodgkin's lymphoma who have not received previous treatment, radioimmunotherapy with Y-90-ibritumomab tiuxetan (Zevalin) improves the response to initial chemotherapy, according to results of a phase II trial in Italy.
Cardiac risk low with dose-dense chemo plus trastuzumab for breast cancer
March 11, 2008
NEW YORK (Reuters Health) - In patients with early stage breast cancer, accelerating the dosing schedule of conventional chemotherapy and adding adjuvant trastuzumab appears to be safe, with low rates of cardiac toxicity, according to researchers at New York's Memorial Sloan-Kettering Cancer Center.
Different risk factors seen for HPV-positive and -negative head and neck cancer
March 11, 2008
NEW YORK (Reuters Health) - Certain sexual behaviors and marijuana use increase the risk of human papillomavirus type-16 (HPV-16)-positive head and neck cancer, whereas tobacco smoking, alcohol use, and poor oral hygiene up the risk of HPV-16-negative disease, US researchers report.
Glaxo says Cervarix shows effect for over 6 years
March 10, 2008
LONDON (Reuters) - GlaxoSmithKline Plc said on Monday its human papillomavirus (HPV) vaccine Cervarix provided significant protection for women against the four most common oncogenic HPV types for 6.4 years, the longest duration of protection reported to date.
Late treatment with letrozole reduces breast cancer recurrence
March 10, 2008
NEW YORK (Reuters Health) - Treatment with the aromatase inhibitor letrozole improves disease-free survival, even when several years have passed since completing 5 years of tamoxifen for treatment of early breast cancer.
Spectrum's Levoleucovorin approved by US FDA for treatment of osteosarcoma
March 10, 2008
LOS ANGELES (Reuters) - The U.S. Food and Drug Administration has approved Spectrum Pharmaceuticals Inc's as a treatment for osteosarcoma the company said on Friday.
Flat colorectal tumors relatively common in US population, linked to cancer
March 4, 2008
NEW YORK (Reuters Health) - Although the focus of colorectal cancer prevention efforts in Western populations is usually on the detection and removal of polypoid neoplasms, findings from a US study indicate that even in this country, flat tumors are fairly common and are more strongly linked to cancer than are polypoid tumors.
Elevated cancer risk seen in ex-hormone users
March 4, 2008
NEW YORK (Reuters Health) - Participants in the Women's Health Initiative (WHI) trial who stopped using estrogen plus progestin when the study was terminated in 2002 appear to be at increased risk for subsequent fatal and nonfatal malignancies compared with subjects who had received placebo, new research shows.
Potent brachytherapy effective against vaginal cancer
March 4, 2008
NEW YORK (Reuters Health) - High-dose rate brachytherapy (HDRB) appears effective for many patients with primary or recurrent cancer of the vagina, according to Pennsylvania-based researchers.
Intensity-modulated radiation therapy is inconsistently delivered
March 3, 2008
NEW YORK (Reuters Health) - Prescribed and delivered doses of intensity-modulated radiation therapy (IMRT) vary widely, researchers report in the March 5th issue of the Journal of the National Cancer Institute. In light of these findings, they call for standardization.
|
